AI Solution for Ulcerative Colitis Launched at DDW 2025 in San Diego

Alimentiv and Dova Health Intelligence (formerly Satisfai Health Inc.) announced the launch of DovaVision™, a new artificial intelligence (AI) solution designed specifically for scoring ulcerative colitis (UC) during clinical trials, at Digestive Disease Week (DDW) in San Diego in 2025. This collaboration marks a significant step forward in the integration of advanced technology into UC research. Overview of DovaVision™ DovaVision™ is an innovative endoscopic interpretation tool tailored for UC clinical trials. It utilizes dynamic frame-level analysis to detect and quantify subtle changes in disease activity, offering more detailed and quantifiable assessments of ulcer severity. This tool supports all phases of UC clinical trials—from Phase I to Phase IV—by enhancing the quality and depth of image data. It provides researchers and sponsors with more precise evaluations of disease severity, accelerating trial progress and improving data consistency and reliability. Development Process The development of DovaVision™ leveraged a comprehensive global database of anonymized inflammatory bowel disease (IBD) colonoscopy videos. These videos were annotated and analyzed in collaboration with Alimentiv's expert centralized readers and medical professionals who have extensive experience in UC scoring and IBD assessment. This combination of high-quality data and clinical expertise ensures that DovaVision™ offers accurate and insightful analyses. Benefits and Applications One of the key benefits of DovaVision™ is its ability to integrate seamlessly with other clinical data sets. By providing consistent, frame-by-frame analysis, it helps researchers identify valuable biomarker correlations, advancing our understanding of disease mechanisms and patient outcomes. The tool's detailed reports and enhanced data insights also promise to lower clinical trial costs and shorten their duration, making it a valuable asset in the pharmaceutical and biotech industries. Leadership Perspectives Solveig Johannessen, CEO of Alimentiv: "In the era of precision medicine, successful clinical trials depend on deep, data-driven insights, not just categorical scores from central readers. DovaVision™ uses explainable AI to analyze endoscopic video data, uncovering more about gastrointestinal disease activity and treatment responses." Dr. Michael Byrne, Founder and Chairman of Dova Health Intelligence: "As a gastroenterologist, I know how critical DovaVision™ will be for UC clinical trials. Its capability for consistent frame-level analysis will help us detect subtle changes and optimize trial design and interpretation." Pierre Gaudreault, CEO of Alimentiv: "We are excited to include this enhanced video analysis capability in Alimentiv’s medical imaging portfolio. With this new AI technology, we can offer sponsors more detailed data analysis, more competitive trial costs, and faster timelines." Current Status and Limitations Currently, DovaVision™ is available solely for research purposes and is provided through Alimentiv's proprietary multimodal imaging review platform, Notō™. This platform offers an end-to-end solution for imaging data analysis and scoring. Despite its robust analytical capabilities, DovaVision™ is not classified as a medical device and cannot be used by healthcare professionals for clinical decision-making, diagnosis, or patient care. Industry Reactions Experts in the field view the introduction of DovaVision™ as a major milestone. They believe it will significantly enhance the quality and efficiency of UC clinical trials, facilitating the development and quicker approval of new treatments. By integrating high-quality global data with cutting-edge AI technology, DovaVision™ is poised to make a substantial impact on clinical research. Company Profiles Alimentiv: Established in 1986, Alimentiv is a leading full-service contract research organization (CRO) specializing in gastrointestinal diseases. The company has a strong global presence and extensive experience in clinical trials, medical imaging, and precision medicine, offering a wide range of services and solutions to the pharmaceutical and biotechnology sectors. Dova Health Intelligence: Headquartered in Vancouver, Canada, Dova Health Intelligence is dedicated to advancing gastrointestinal care and research through computer vision and data-driven diagnostic technologies. The company’s suite of tools, including DovaVision™ and DovaSound, aims to support clinical decision-making, drug innovation, and improve patient outcomes. Dova collaborates closely with top researchers, clinicians, and industry partners to deliver actionable insights where they are most needed. Conclusion The launch of DovaVision™ at DDW 2025 represents a significant advancement in the use of AI for gastrointestinal disease assessment. By providing deeper, more precise data insights, this tool promises to streamline UC clinical trials, reduce costs, and speed up the development of new treatments. Industry experts and company leaders highlight its potential to revolutionize the field, making it a promising addition to the medical research landscape. Both Alimentiv and Dova Health Intelligence are well-positioned to drive further innovations in precision medicine and clinical trials, ultimately benefiting patients and advancing medical knowledge.